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Background. Cytolytic Shiga toxins (Stx) are believed to be
largely responsible for renal damage in post-diarrheal hemolytic-
uremic syndrome (D1HUS). Despite the general belief that
endothelial cells are the primary target of Stx, there is evidence
that proximal tubules may be a site of toxin action. We hypothe-
sized that cultured proximal tubular cells are sensitive to the
cytotoxic effects of Stx.
Methods. Cultured human proximal tubular cells were exposed
to Stx-1 in the presence and absence of a variety of inflammatory
factors likely to be elevated in the kidney or serum of patients with
D1HUS. Cell survival, protein synthesis, total cell levels and
synthesis of Stx receptors (GB3), and Stx binding were measured.
Results. Proximal tubules were extremely sensitive to the cyto-
toxic effect of Stx-1 with an LD50 at least equal to, if not less than,
that seen with Vero cells. Interleukin-1 (IL-1), lipopolysaccharide
(LPS), and butyrate (but not tumor necrosis factor or interleu-
kin-6) up-regulated proximal tubule sensitivity to Stx-1. IL-1
increased Stx-1 binding, but did not alter total cell levels or
synthesis of GB3, the glycosphingolipid receptor for Stx-1. In
contrast, LPS and butyrate, despite increasing Stx-1 sensitivity,
had no effect on Stx-1 binding.
Conclusions. These studies indicate that proximal tubules are
exquisitely sensitive to Stx-1 cytotoxicity and that inflammatory
factors can increase toxin responsiveness through a variety of
mechanisms. It is suggested that proximal tubules may be an
important early target of Stx-1 action in D1HUS.
Post-diarrheal hemolytic-uremic syndrome (D1HUS) is
the leading cause of acute renal failure in children [1, 2]. It
has been generally thought, on the basis of histologic
studies, that the predominant renal features of D1HUS
are glomerular and arteriolar endothelial cell swelling and
detachment, fibrin accumulation, and thrombosis [2, 3].
Renal endothelial cell damage in D1HUS is related to
enteric infection by Shiga toxin (Stx) producing organisms
(typically E. coli 0157:H7) [2, 4]. Stx binds to galactose-a-
1,4, galactose-b-1,4, glucose-ceramide (GB3), is internal-
ized, and ultimately is cytotoxic, at least in part, by directly
inhibiting peptide elongation [1]. The observation that
renal microvascular endothelial cells, at least in culture,
express relatively high amounts of GB3 on their surface has
been used to explain renal targeting in D1HUS [3, 5]. This
apparently straightforward scenario of renal damage in
D1HUS is complicated, however, by observations suggest-
ing that: (1) endothelial cells may not be the initial or the
most sensitive renal cellular target of Stx, and (2) Stx
cytotoxicity may depend, at least partially, on its concerted
action with other inflammatory factors.
With regards to non-endothelial cell targets of Stx action
in the kidney, the proximal tubule has emerged as a likely
possibility. First, administration of Stx to transgenic mice
bearing the chloramphenicol acetyltransferase reporter/
tumor necrosis factor promoter (CATTNF) construct in-
duced TNF promoter activity primarily in the kidney [6].
Since Stx-treated rodents develop only tubulointerstitial
disease [6], this suggested a tubular target for Stx. Second,
Stx receptors (GB3) are found in abundance on renal
cortical tubular epithelial cells in humans [3, 7]. Third,
when kidneys from patients with D1HUS are examined
very early in the course of the disease, histologically
apparent proximal tubular damage is evident [2]. Finally,
urinary excretion of markers of proximal tubular damage is
elevated early in the course of D1HUS [2]. Hence, the
proximal tubule may be an important, yet relatively unrec-
ognized, site of Stx action. The first goal of the current
study was, therefore, to examine the cytotoxic effect of Stx
on human proximal tubular cells.
As alluded to above, Stx cytotoxicity may be potentiated
by other inflammatory factors. For example, interleukin
(IL)-1 and IL-6 and TNF are secreted by macrophages in
response to Stx [8]; IL-1 and TNF can, in turn, potentiate
the cytotoxic effect of Stx on human umbilical vein endo-
thelial cells (HUVEC) [9, 10]. In addition, lipopolysaccha-
ride (LPS) is likely to be present in the blood of D1HUS
patients [1, 2] and can also enhance Stx cytotoxicity on
HUVEC [10]. Furthermore, butyrate, which may be ele-
vated in the circulation of patients with D1HUS due to
disruption of colonic epithelium, sensitizes HUVEC to Stx
toxicity [11]. Hence, while Stx may play a central role, it
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would be important to examine the cytotoxic effects of Stx
when administered together with inflammatory factors
likely to be elevated in the circulation and/or the kidneys of
patients with D1HUS. Accordingly, the second goal of the
current study was to examine the effect of inflammatory
factors to modify Stx cytotoxicity on human proximal
tubular cells.
METHODS
Reagents
Human proximal tubular cells were obtained from Clo-
netics, Inc. (San Diego, CA, USA). Vero cells (African
Green Monkey kidney) were obtained from American
Type Tissue Collection (ATCC #CRL-81; Rockville, MD,
USA). Fetal bovine serum was from Hyclone (Logan, UT,
USA); glacial acetic acid from Mallinckrodt (Paris, KY,
USA); ethanol from Quantum Chemical Co. (Anaheim,
CA, USA); trypsin/EDTA, penicillin/streptomycin, L-glu-
tamine, insulin, transferrin, selenium, epidermal growth
factor, Dulbecco’s modified Eagle media:Ham’s F12
(DMEM:F12), DMEM, Hank’s balanced salt solution
(HBSS), and M199 were purchased from Gibco/BRL
(Gathersburg, MD, USA); and polyisobutylmethacrylate
from Aldrich Chemical Corp., (Milwaukee, WI, USA). All
tissue culture flasks, dishes, and multiwell plates were
Falcon Brand (Becton Dickinson, Lincoln Park, NJ, USA).
3H-leucine and 125I-goat anti-mouse IgG were from Du-
Pont NEN (Boston, MA, USA), Na 125I from ICN (Costa
Mesa, CA, USA), and UDP-14C galactose was from Am-
ersham (Arlington Heights, IL, USA). Recombinant IL-1b
(IL-1), IL-6, and TNF-a (TNF) were from R & D Systems
(Minneapolis, MN, USA). Lactosylceramide and globotri-
aosylceramide (GB3) were from Matreya (Pleasant Gap,
PA, USA).
Cell culture
Human proximal tubular cells were studied at the third
passage. Proximal tubular cell identity and purity has been
extensively characterized (Clonetics). In addition, we de-
termined that these cells lacked von Willebrand factor, Thy
1.1, PECAM, P-selectin, and thrombomodulin immunoflu-
orescence, but were positive for cytokeratin immunofluo-
rescence and alkaline phosphatase activity. Proximal tubu-
lar cell cultures were maintained in 1:1 DMEM:F12
containing 25 mM HEPES, 2 mM L-glutamine, 100 U/ml
penicillin/streptomycin, 250 mg/liter amphotericin B, 1
mg/ml hydrocortisone, 10 mg/ml insulin, 5.5 mg/ml trans-
ferrin, 6.7 mg/ml selenium, 0.2 g/liter ethanolamine, 6.5
ng/ml L-thyroxine, 10 ng/ml epidermal growth factor, and
10% fetal bovine serum (FBS) at 37°C in a 5% CO2
incubator. For growth-arrest studies, barely confluent prox-
imal tubular cell cultures were placed in DMEM:F12
containing only L-glutamine and penicillin/streptomycin
for 24 hours prior to any experimental maneuvers. All
studies were performed under growth-arrested conditions.
Vero cells were grown and studied in M199 containing
2.2 g/liter sodium bicarbonate, 25 mM HEPES, 100 U/ml
penicillin/streptomycin, and 5% FBS.
Neutral red cytotoxicity assay
The neutral red cytotoxicity assay was adapted from
previously described protocols [12, 13]. Confluent Vero or
proximal tubular cells in 96 well plates were exposed to
Stx-1 isolation column fractions (see below), 1025 to 10211
g/ml Stx-1, or 0.1 to 100 mM cycloheximide for 0, 24, 48, 72,
or 96 hours. Two hundred microliters of neutral red media
(50 mg/ml neutral red in M199 containing 5% FBS) was
then added to each well and incubated for 2 to 3 hours at
37°C in a 5% CO2 incubator. Cells were then washed with
200 ml 1% CaCl2 1 1% formaldehyde and solubilized in
200 ml 1% acetic acid in 50% ethanol. Absorption was read
at 450 nm on a Molecular Devices ThermoMax Microplate
reader (Menlo Park, CA, USA).
For studies examining the effect of inflammatory factors
on Stx-1 or cycloheximide toxicity, proximal tubular cells
were incubated with varying concentrations of LPS, bu-
tyrate, IL-1, IL-6, or TNF for 4, 24, or 48 hours in
growth-arrest media before addition of the cytotoxic agent.
Subsequently, Stx-1 or cycloheximide were added to the
media already on the cells and incubated for an additional
72 hours, followed by analysis of neutral red uptake.
3H leucine incorporation
Proximal tubular and Vero cells were grown and assayed
in 24 well plates. Cells were exposed to 1025 to 10211 g/ml
Stx-1 or 0.1 to 100 mM cycloheximide for 24, 48, 72, or 96
hours. The media was then removed and 250 ml of room
temperature HBSS containing 1 mCi/ml 3H-leucine was
added at room temperature and maintained for 20 minutes.
Cells were then rinsed with ice cold HBSS and solubilized
in 500 ml 0.1% sodium dodecyl sulfate (SDS). A 200 ml
aliquot was mixed with 25 ml of 200 mg/ml bovine serum
albumin and 2 ml 10% tricarboxylic acid (TCA). The
precipitate was incubated on ice for 60 minutes, collected
on pre-wetted GF/C filters (Whatman, Kent, England, UK)
through a vacuum manifold, the filters washed with 10%
ice-cold TCA followed by ice-cold 95% ethanol, and air-
dried. Filters were added to scintillation vials with 5 ml
Ready Safe scintillation cocktail (Beckmann, Fullerton,
CA, USA) and cpm determined with a Packard 2200CA
beta-counter (Downers Grove, IL, USA)
Isolation and quantitation of GB3
Proximal tubular and Vero cells were grown in six well
plates and growth arrested at confluence. Proximal tubular
cells were stimulated with inflammatory factors for 24
hours followed by extraction of total cellular lipids as
previously described [14–17]. Cells were washed with ice
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cold PBS, scraped off the plates, and centrifuged at 1500
rpm. The cell pellet was extracted three times in 1 ml of
5:10:3 chloroform:methanol:water and dried under vac-
uum. The dried total lipid product was suspended in 2:1
chloroform:methanol and separated on high performance
thin layer chromatography-silica plates (Mallinckrodt
Baker Inc., Paris, KY, USA) by ascending chromatography
in 50:40:10 chloroform:methanol:water containing 0.025%
CaCl2. GB3 standards were run on each plate to permit
GB3 quantitation. Total neutral lipid content was deter-
mined by running duplicate plates and visualizing lipids
with Orcinol spray.
For immunostaining, the above plates were dried, im-
mersed in 0.5% polyisobutylmethacrylate in acetone for
one minute, and dried. Plates were then incubated in Tris
buffered saline-Tween 20 (TBST; 10 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.5% Tween 20) containing 10% goat serum
for 30 minutes, washed in 2% goat serum/TBST, incubated
with 1.5 mg/ml Stx-1 in 2% goat serum/TBST for two hours,
washed, incubated with 5 mg/ml anti-Stx-1 monoclonal
antibody (13C4, see below) in 2% goat serum/TBST for one
hour, washed, and incubated with 0.1 mg/ml 125I-goat
anti-mouse IgG in 2% goat serum/TBST for one hour.
Plates were then washed, air dried, and specific binding
visualized by autoradiography. GB3 concentrations were
calculated by densitometry using Gaussian density distribu-
tion with Eagle Eye II ONE-Dscan software (Stratagene,
La Jolla, CA, USA).
Results of GB3 quantitation were standardized for cell
number by cell counting and total protein determination.
Prior to centrifugation and lipid extraction, a small aliquot
of cells was solubilized in 0.1 N NaOH, mixed with Bradford
reagent (Bio-Rad, Richmond, CA, USA) and protein con-
centration determined by measuring absorbance at 590 nm
[18]. Quantitative comparisons between GB3 in different
cell types or under different experimental conditions did
not differ whether the data were expressed per total cell
protein or cell number. For simplicity, all data are ex-
pressed per cell number.
UDP-galactose lactosylceramide galacosyltransferase
(GalT6) assay
Proximal tubular cells were grown in 10 cm dishes and
growth arrested at confluence. Cells were then stimulated
with inflammatory factors for 24 hours, scraped and cen-
trifuged at 1500 rpm. The pellet was resuspended in 500 ml
50 mM MES pH 6.5. Cells were disrupted with a five
seconds pulse from an ultrasonic tip processor (amplitude
30 at 25 watts; Cole Parmer Instrument Co., Chicago, IL,
USA) and assayed for total protein using the Bradford
method. GalT6 activity was assayed using a modification of
the method by Mobessaleh, Mishra and Keusch [17].
Lactosylceramide (LacCer, 25 nmoles) was aliquoted in 2:1
chloroform:methanol and dried in polypropylene micro-
centrifuge tubes under vacuum. Sodium cholate in water
(250 mg) was added to the dried LacCer, dried under
vacuum, and the dried mixture incubated for 60 minutes at
4°C. A total volume of 100 ml 50 mM MES pH 6.5
containing 10 mM MnCl2, 100 mM 59-adenylimidodiphos-
phate [p(NH)ppA], 250 mM cold UDP-galactose, 44 mM
UDP-14C galactose (150,000 to 400,000 cpm), and 125 mg
total cellular protein was added to the dried LacCer/
sodium cholate, the samples were vortexed briefly, incu-
bated in a slowly agitating 37°C water bath for 60 minutes,
and the reaction stopped by adding 1 ml 2:1 chloroform:
methanol. A Folch partition was established by adding 200
ml 0.1 M KCl and the upper phase re-extracted by adding
500 ml 2:1 chloroform:methanol. The lower phase was
reextracted by adding 500 ml 1:1 methanol:0.1 M KCl. The
lower phases (containing the neutral lipids) were com-
bined, dried under vacuum, and chromatographed as de-
scribed for GB3 above.
Purification of Shiga toxin-1
Stx-1 was purified (according to a modification of previ-
ously described protocols [19]) from E.coli HB101 contain-
ing pNAS13 (gift of Alison D. O’Brian, Uniformed Services
University of the Health Sciences, Bethesda, MD, USA), a
derivative of pNAS4 [20] that contains a 3.4 kb NcoI
fragment encoding Stx-1. The crude toxin preparation from
bacterial lysates was dialyzed extensively against 50 mM
Tris-HCl (pH 8), subjected to CL-6B DEAE-Sepharose
(Pharmacia, Uppsala, Sweden) anion-exchange chromatog-
raphy using the same buffer, and eluted with a 0 to 0.5 M
NaCl gradient in the same buffer. Fractions were pooled
based on their cytotoxicity to Vero cells and dialyzed
against phosphate-buffered saline (PBS), pH 7.4. Crude
toxin was then concentrated and subjected to immunoaf-
finity chromatography with a monoclonal antibody to the
B-subunit of Stx-1 (13C4, see below) linked to an Amin-
oLink column (Pierce, Rockford, IL, USA). Eluted sam-
ples were tested for cytotoxicity on Vero cells and protein
directly visualized by electrophoresis on 15% native and
denaturing polyacrylamide gels. Cytotoxic fractions were
combined, concentrated and dialyzed against PBS (pH 7.4).
LPS contamination was determined to be minimal using an
E-Toxate assay (Sigma). Toxin used for all cell culture
experiments was purified a second time over the immuno-
affinity column, concentrated and dialyzed against PBS.
Toxin concentration was based on spectrophotometric
O.D. and Bradford protein assay.
Iodination and binding of Shiga toxin-1
Stx-1 was iodinated according to the Iodobead manufac-
turer’s protocol (Pierce, Rockford, IL, USA). Two iodo-
beads were mixed with 80 ml PBS and 1 mCi Na125I,
incubated five minutes, 10 mg Stx-1 in 20 ml PBS added for
10 minutes, and the reaction quenched with 100 ml 0.1 M K
iodide. The mixture was added to a 5 ml De/Salt column
pre-equilibrated with PBS (Pierce), 2 ml PBS added, and
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five drop fractions collected and cpm determined on a
Packard 5000 gamma counter. Fractions with the highest
radioactivity were pooled and purity determined by SDS-
PAGE. Only one band was seen corresponding to the B
subunit of Stx-1. In addition, the toxicity of the labeled
Stx-1 was verified using Vero cells.
For 125I-Stx-1 binding assays, proximal tubule cells in 96
well plates were pre-incubated in growth-arrest media for
24 hours with or without inflammatory cytokines. Vero cells
were also studied, but without altering their media compo-
sition. At the time of study, media was removed and 17,000
cpm of 125I-Stx-1 in 100 ml M199 containing 5% FBS and 25
mM HEPES plus varying concentrations of unlabeled Stx-1
was added for 24 hours at 4°C. Cells were then rinsed with
ice-cold HBSS, solubilized in 0.1 N NaOH, and cpm deter-
mined on a Packard 5000 gamma counter.
Mouse anti-Shiga toxin-1 monoclonal antibody
purification
A mouse monoclonal antibody to the B-subunit of Stx-1
[21] was purified from a hybridoma cell line, 13C4 (ATCC,
Rockville, MD, USA), using standard protocols [22]. Puri-
fied monoclonal antibody was tested on Vero cells for its
ability to neutralize Stx-1. The final antibody preparation at
a concentration of 3 mg/ml completely neutralized the
cytotoxic effect of 1 ng/ml Stx-1 on Vero cells. A Western
blot on a 15% SDS-PAGE gel confirmed that the purified
antibody recognized only the B subunit of Stx-1 (gift of
Arthur Donahue-Rolfe, Tufts University, MA, USA).
Statistics
All data were analyzed by one way analysis of variance.
Results are expressed as mean 6 SEM. P values , 0.05 were
taken as significant. Wherever the data are expressed as
percent of control, the sample size (N) refers to the number
of experimental and control samples used for that particu-
lar data point.
RESULTS
Shiga toxin-1-induced cytotoxicity and protein synthesis
inhibition
Cytotoxicity was assessed by a combination of neutral red
uptake, total cell protein, cell number, and cell morphol-
ogy. The Figures illustrate neutral red uptake, however, the
total cell protein and cell number generally paralleled
neutral red uptake. Neutral red uptake was preferrred
because when cell death exceeded about 50 to 60%, many
of the cells did not detach. The undetached cells, which
were often extremely granular and irregularly shaped,
would be included in total protein and cell number deter-
minations, but would not take up neutral red. Alterations in
cell morphology generally agreed with neutral red uptake:
marginally toxic concentrations of Stx-1 mildly increased
cytoplasmic granularity, while higher toxin concentrations
gradually increased cytoplasmic granule number and size,
which caused irregular cell borders, cell flattening, and
ultimately led to cell detachment.
Stx-1 dose-dependently killed human proximal tubular
cells in culture (Fig. 1). The toxic effect of Stx-1 was readily
detectable by 24 hours with approximately 30% of cells
surviving the highest concentrations of toxin. No cells
survived incubation with toxin concentrations $ 1027 g/liter
(100 pg/ml or 1.35 pM) for 48 hours or longer. The LD50 of
Stx-1 was approximately 1029 g/liter (1 pg/ml or 10.4 fM). By
way of comparison, Vero cells did not respond to Stx-1 as
quickly as did proximal tubular cells (Fig. 2). The LD50 of
Stx-1 for Vero cells increased with length of exposure to the
toxin, ranging from 1026 g/liter (1 ng/ml or 10.4 pM) after 24
hours exposure to 10210 g/liter (100 fg/ml or 1 fM) after 96
hours. 125I-Stx-1 binding to Vero and proximal tubular cells
was similar (Fig. 3), while proximal tubular cells contained
more total cellular GB3 (3.12 6 0.15 mg/107 cells) than did
Vero cells (0.64 6 0.086 mg/107 cells; N 5 3; P , 0.001; Fig.
4).
Stx-1 also dose-dependently inhibited protein synthesis
by human proximal tubular cells as assessed by 3H-leucine
incorporation (Fig. 5). Even after 24 hours of exposure,
Stx-1 almost completely blocked protein synthesis at 1029
g/liter. Cell death lagged behind protein synthesis inhibi-
tion, with approximately a 5- to 10-fold higher concentra-
tion of Stx-1 being required to kill, as compared to inhibit,
protein synthesis in 50% of the cells.
Inflammatory factor modulation of Shiga toxin-1
cytotoxicity
The effect of IL-1, IL-6, TNF, LPS, and butyrate on the
cytotoxic effect of Stx-1 on human proximal tubular cells
was examined. None of these agents alone significantly
affected neutral red uptake. Of the inflammatory cytokines,
IL-1 (Fig. 6A), but not IL-6 or TNF (Fig. 6 B, C), enhanced
Stx-1 sensitivity (Stx-1 dose chosen that caused approxi-
mately a 50% reduction in cell viability at 72 hr). The effect
of IL-1 was most evident at 24 hours, but was manifest by
four hours. It is important to note that the incubation times
refer to the length of time cells were incubated with the
cytokine prior to addition of Stx-1. When the cytokines
were added at the same time as Stx-1 was added, there was
no up-regulation of Stx-1 cytotoxicity (data not shown). It
was not possible to determine the minimal concentration of
IL-1 required to increase Stx-1 cytotoxicity from the current
study: a clear dose-response was not obtained. This was not
pursued further since our primary goal was to document an
up-regulation, and not to determine the full range of
physiological concentrations of the regulatory substances.
LPS and butyrate also augmented Stx-1 cytotoxicity in
human proximal tubular cells (Fig. 6 D, E). LPS up-
regulation occurred at a concentration as low as 0.1 mg/ml,
but like IL-1, was not dose-dependent. We did not extend
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the concentrations lower to determine the minimal effec-
tive concentration of LPS. In contrast, butyrate caused a
clear dose-dependent up-regulation of Stx-1 sensitivity,
with the maximal effect evident after a 48 hour exposure to
5 mM butyrate. It should be noted that the highest concen-
tration of butyrate (5 mM), while not significantly reducing
cell viability, caused proximal tubule cells to become quite
granular and flattened, which are findings usually seen
when cells begin to die.
Mechanism of inflammatory factor up-regulation of
Shiga toxin-1 cytotoxicity
Modulation of cycloheximide cytoxicity. To test the speci-
ficity of inflammatory factor modulation of Stx-1 action, the
effect of these agents on cycloheximide (CHX), a protein
synthesis inhibitor and cytotoxic agent, was examined. It
was first necessary to determine a CHX concentration that,
like the Stx-1 concentration used in the above studies,
caused approximately a 50% reduction in cell viability. A
dose (0.1 to 100 mM)- and time (4 to 48 hr)-response curve
revealed that 5 to 10 mM CHX killed approximately 30 to
60% of proximal tubular cells between 48 to 72 hours (N 5
12 each data point), while 5 mM CHX caused a 50%
reduction in 3H-leucine incorporation between 48 to 72
hours (N 5 6 each data point). Hence, a 72 hour exposure
to 10 mM CHX was used for subsequent studies.
IL-1, IL-6, TNF, and LPS pre-incubation for 4 to 48
hours at the concentrations used with Stx-1 had no effect on
CHX cytotoxicity (N 5 6 each data point). Butyrate did
slightly increase CHX cytotoxicity (82 6 10% of CHX
alone, P , 0.05), but only at the highest dose and longest
exposure time (5 mM for 48 hr). In addition, the butyrate
effect was much less pronounced on CHX toxicity as
compared to that with Stx-1.
Modulation of GB3 expression, GalT6 activity, and SLT-1
binding. Inflammatory factor regulation of total cell GB3
levels was determined. An incubation time of 24 hours and
the maximal stimulatory concentration of inflammatory
substance were chosen since these conditions significantly
up-regulated Stx-1 cytotoxicity (see above). Only butyrate
increased total cell GB3 content; even the butyrate effect,
while statistically significant, was very small (Fig. 7).
Since an increase in total cellular GB3 content could be
due to increased GB3 synthesis, the effect of the inflam-
matory factors on GalT6 activity was determined. No factor
increased total GalT6 activity (Fig. 8); butyrate tended to
give the highest enzyme activity, but it did not achieve
statistical significance. It should be noted that we did not
examine the nature of the tertiary galactose bond in the
GB3 product obtained in the GalT6 assay because this was
not felt to be necessary (see discussion).
To test whether cell surface expression of GB3 or some
other Stx-1 receptor could be increased by inflammatory
factors, proximal tubular cells were incubated with the
various agents for 24 hours, followed by determination of
Fig. 1. Cytotoxic effect of Shiga toxin-1 (Stx-1)
on human proximal tubular cells (N 5 12 each
data point).Cells were incubated with Stx-1 for
varying times, followed by determination of
neutral red uptake. Symbols are: (E) 24 hr; (F)
48 hr; () 72 hr; () 96 hr.
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125I-Stx-1 binding in the presence of increasing concentra-
tions of unlabeled Stx-1. While a Kd and Bmax could
potentially be estimated from these curves, such calcula-
tions were not made since it was extremely difficult to know
the precise molar concentration (and hence specific activ-
ity) of 125I-Stx-1 due to difficulties in measuring very small
concentrations of Stx-1 recovered from the iodination
process. Nonetheless, it appears that IL-1 increased total
Stx-1 binding and also appeared to increase Stx-1 affinity
(curve shifted to the right; Fig. 9). LPS and butyrate, while
enhancing Stx-1 cytotoxicity, had no effect on Stx-1 binding
or GB3 content.
DISCUSSION
The first goal of the current study was to examine the
cytotoxic effect of Stx on human proximal tubular cells. Our
results indicate that proximal tubular cells are exquisitely
sensitive to Stx-1, with an LD50 for the toxin at least equal
to, if not less than, that seen with Vero cells. This finding is
supported by previous observations that human renal ade-
nocarcinoma cells, purportedly of epithelial origin, are very
sensitive to Stx-1 cytotoxicity (LD50 ; 1 pg/ml) [23] as well
by clinical findings that renal biopsies performed early in
the course of D1HUS reveal proximal tubule damage [2].
It is important to note that all proximal tubular cell cultures
were studied under growth-arrested conditions. The prolif-
erative state can alter Stx sensitivity: actively growing cells
are more susceptible to the toxin than are quiescent cells
[24]. We also examined the effect of Stx-1 on proliferating
proximal tubular cells and found that Stx-1 sensitivity was
increased approximately 50-fold (data not shown). Thus,
proximal tubular cells may be even more sensitive to Stx-1
than are Vero cells (Vero cells studied above were actively
proliferating). Nonetheless, despite this enhanced cytotoxic
effect of Stx-1 on proliferating proximal tubule cells, the
current studies were conducted exclusively under growth-
arrested conditions. This was necessary because, even at
very low concentrations of serum and other growth factors,
proximal tubular cells grow so fast that they become
overconfluent during the time course of the studies, con-
founding any interpretation of cell survival. Furthermore,
since GB3 expression may vary with growth state [24], we
wanted to avoid differences in Stx-1 sensitivity due to
fluctuations in the proliferative state of the cells.
The reason for such a high sensitivity of proximal tubular
cells to Stx-1 may be due, at least in part, to their relatively
abundant expression of Stx-1 receptors. The current study
demonstrates that the total cell GB3 content is at least as
high in proximal tubular as in Vero cells. Since GB3
content has been shown to parallel Stx sensitivity [10, 11,
25, 26], this suggests that high proximal tubular cell GB3
expression may enhance susceptibility to the toxin. The
current study also documented high Stx-1 binding by prox-
imal tubule (similar to that seen with Vero cells). While it
is conceivable that Stx-1 may bind to receptors other than
glycosphingolipids with a gala1-4 gal linkage, these binding
Fig. 2. Cytotoxic effect of Shiga toxin-1 (Stx-1)
on proliferating Vero cells. N 5 12 each data
point). Cells were incubated with Stx-1 for
varying times, followed by determination of
neutral red uptake. Symbols are: (E) 24 hr; (F)
48 hr; () 72 hr; () 96 hr.
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studies also support the notion that proximal tubular cell
sensitivity to Stx-1 relates, at least partially, to abundant cell
surface GB3 expression. Finally, it should be emphasized
that these arguments should not be construed to imply that
proximal tubular cell responsiveness to Stx-1 is solely
determined by GB3 expression. For example, fusion of
GB3 liposomes with GB3-deficient, Stx-1 resistant CHO
cells increases toxin binding but does not confer Stx
cytotoxicity [27]. Thus, proximal tubular cell sensitivity to
Stx-1 may also be due to enhanced intracellular responsive-
ness to the toxin. As will be discussed below, this latter
possibility does appear to be the case in some circum-
stances in proximal tubule cells.
While a full investigation of the mechanisms by which
Stx-1 kills proximal tubular cells was beyond the scope of
the current study, it is important to discuss the means by
which such toxicity occurs. Two major mechanisms for
Stx-1 action have been proposed: cell necrosis as a result of
protein synthesis inhibition and apoptosis. That protein
synthesis blockade occurred and that cells died at toxin
concentrations that inhibited protein synthesis was docu-
mented in the current study. It seems reasonable to assume
Fig. 3. Competition binding assay of 125I-Stx-1
to human proximal tubular cells (F) and
proliferating Vero cells (E). N 5 6 each data
point. Approximately 84,000 cpm of 125I-Stx-1
were added per well for 24 hours at 4°C, cells
washed, solubilized, and bound cpm
determined.
Fig. 4. Total globotriaosyl ceramide (GB3) content in human proximal tubular (Prox. Tub.) and proliferating Vero cells. A standard curve using
purified GB3 is shown on the left side of the autoradiogram for comparison. Each experimental lane represents a different cell culture preparation.
Details are in the Methods section.
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that concentrations of Stx-1 that completely blocked pro-
tein synthesis in proximal tubule cells resulted in cell
necrosis; however, lower toxin concentrations that did not
fully block protein synthesis may not necessarily have
caused cell necrosis. That partial protein synthesis inhibi-
tion and cell death are not strictly correlated has recently
been documented. van Setten et al noted that partial
inhibition of protein synthesis in mesangial cells by Stx-1
was not associated with reduced cell viability [28]. It is
therefore conceivable that Stx-1 induces apoptosis in hu-
man proximal tubular cells, particularly at concentrations
that do not fully block protein synthesis. This possibility is
supported by findings that Stx causes apoptosis in LLC-PK1
cells, a proximal tubule-like cell line [29], as well as in
Burkitt’s lymphoma cells [30]. Ultimately, detailed studies
will be needed exploring the role of apoptosis in Stx-1
cytotoxicity in human proximal tubule cells.
The second goal of the current study was to examine the
effect of inflammatory factors on Stx cytotoxicity in human
proximal tubular cells. This was done since we wanted to
study proximal tubular sensitivity to Stx-1 in the context of
inflammatory factors likely to be present in their environ-
ment during the course of D1HUS. Further, it is known
that some of these substances (IL-1, TNF, LPS and bu-
tyrate) potentiate the cytotoxic effect of Stx on HUVEC
[9–11]. It should also be noted at this juncture that
inflammatory factor up-regulation of Stx sensitivity was not
a given. While TNF augments Stx-1 cytotoxicity in HUVEC
and human glomerular endothelial cells [26, 31], it has no
such effect on human renal microvascular endothelial cells
[26]. Hence, time courses and limited dose-responses were
performed for IL-1, IL-6, TNF, LPS, and butyrate modu-
lation of proximal tubular responsiveness to Stx-1.
The results of inflammatory factor regulation of proximal
tubular cell sensitivity to Stx-1 were surprisingly complex.
First, IL-1 clearly augmented the cytotoxic effect of Stx-1
on proximal tubular cells. This effect was specific since the
cytokine did not enhance CHX toxicity. Interestingly, IL-1
did not detectably alter total cell GB3 content or GalT6
activity, yet it enhanced Stx-1 binding. This could be
explained by increased cell surface GB3 expression due to:
(1) increased GB3 translocation to, or reduced removal
from, the plasma membrane; or (2) a small overall increase
in cell GB3 content that was undetectable in the setting of
very high basal GB3 levels. Alternatively, IL-1 could induce
expression of other, as yet unidentified, Stx-1 receptors. It
should be noted that the data qualitatively suggest that IL-1
increased both the Bmax and the Kd for Stx-1 binding. Such
a result might be obtained by increased cell surface GB3
expression, particularly if Stx-1 binding involved positive
cooperativity (thereby increasing Kd as well as Bmax).
Caution must be used, however, in any interpretation of the
binding kinetics since strict quantitative analysis, especially
if cooperative binding is involved, could not be accurately
Fig. 5. Effect of Shiga toxin-1 (Stx-1) on 3H-
leucine uptake by human proximal tubular
cells. N 5 6 each data point. Cells were
incubated with Stx-1 for varying times followed
by addition of 1 mCi/ml 3H-leucine for 20
minutes. Control 3H-leucine uptake was 2208
cpm/mg total cell protein or 253 cpm/plate.
Symbols are: (E) 24 hr; (F) 48 hr; () 72 hr;
() 96 hr.
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Fig. 6. Effect of IL-1 (A), IL-6 (B), TNF (C), LPS (D), or butyrate (E)
on Shiga toxin-1 (Stx-1) (1029 g/liter) cytotoxicity on human proximal
tubular cells. N 5 8 each data point. *P , 0.05; **P , 0.01; #P ,
0.001 (all P values versus Stx-1 alone). Cells were pre-incubated with
inflammatory factors for 24 hours prior to exposure to Stx-1 for 72
hours and subsequent determination of neutral red uptake. Symbols in
A and C are: (f) 10 U/ml; (M) 100 U/ml; (u) 1000 U/ml. Symbols in B
and E are: (f) 0.5 ng/ml; (M) 2 ng/ml; (u) 5 ng/ml. Symbols in D are:
(f) 0.1 mg/ml; (M) 1 mg/ml; (u) 10 mg/ml.
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performed. Taken together, these data indicate that IL-1
enhances proximal tubular cell sensitivity to, and binding
of, Stx-1 without detectably altering total cell GB3 levels or
synthesis. Such an observation has not been previously
described. Indeed, IL-1 up-regulation of Stx-1 cytotoxicity
has always been associated with increased GB3 content and
synthesis [9, 10, 25].
Neither IL-6 nor TNF altered proximal tubular cell
sensitivity to Stx-1 or CHX. Similarly, neither cytokine
changed proximal tubule GB3 content, GalT6 activity, or
Stx-1 binding. The effect of IL-6 on Stx-1 cytotoxicity in any
cell type, to our knowledge, has not been previously
examined. As alluded to above, TNF has been reported to
increase Stx-1 toxicity in HUVEC (presumably through
up-regulation of GB3 expression [10, 25, 32]), yet does not
affect human renal microvascular endothelial cells [26].
The reasons for such different cell sensitivities to TNF are
unknown.
Both LPS and butyrate increased proximal tubular cell
sensitivity to Stx-1, but unlike IL-1, this stimulatory effect
was unassociated with altered Stx-1 binding. LPS increased
the GB3 content in HUVEC [26], however, the endotoxin
had no effect on total GB3 levels or GalT6 activity in
proximal tubule cells. Therefore, the mechanism by which
LPS up-regulates Stx-1 cytotoxicity in proximal tubular cells
must involve steps distal to Stx-1 binding. It is important to
note that LPS enhancement of Stx-1 action is not due to a
non-specific toxic effect since LPS did not alter CHX
toxicity. Finally, the mechanism of butyrate up-regulation
of proximal tubule sensitivity to Stx-1 is particularly com-
plex. Butyrate caused a slight, yet significant, increase in
proximal tubular cell GB3 content, but no detectable
increase in GalT6 activity or Stx-1 binding. Since the
increase in GB3 was so small, caution must be used to avoid
overinterpreting the meaning of increased GB3 levels in
the absence of altered GalT6 activity or Stx-1 binding.
Nonetheless, these results could be explained by reduced
GB3 degradation together with reduced cell surface GB3
expression relative to total cell GB3 content. Alternatively,
it is possible that while total GalT6 activity was unchanged,
butyrate may have altered the form of GB3 that was
synthesized. The GB3 assay employed in the current study
detects GB3, in part, by Stx-1 binding to the chromatogra-
phy plate. In contrast, the GalT6 assay measures synthesis
of GB3 by addition of galactose to lactosylceramide, but
does not assess the ability of newly synthesized GB3 to bind
Stx-1 (the assay, at least in our hands, is not this sensitive).
Since galactose could be added in a b1-3 linkage (does not
bind Stx-1) or an a1-4 linkage (binds Stx-1), it is possible
that butyrate caused a relative shift to a1-4 linkages without
an overall increase in GalT6 activity. This possibility might
be tested by quantitating GalT6 activity in the presence and
absence of a- or b-galactosidases. Such studies were not
done since, as mentioned above, the increase in total GB3
was small and there was no change in Stx-1 binding induced
by butyrate. It is relevant that the one study in which
butyrate increased HUVEC Stx-1 cytotoxicity revealed a
sixfold increase in Stx-1 binding [11]. Taken together, the
most likely explanation for butyrate up-regulation of prox-
imal tubular cell Stx-1 sensitivity appears to involved steps
distal to Stx-1 binding. Finally, it should be noted that 48
hours of exposure to the highest concentration of butyrate
Fig. 7. Effect of 24 hours of incubation with 100 U/ml IL-1, 5 ng/ml IL-6,
1000 U/ml TNF, 1 mg/ml LPS, or 5 mM butyrate on total GB3 content in
human proximal tubular cells. N 5 6 each data point. *P , 0.025 versus
control. Lanes were loaded with an equal weight of total cellular lipids
(details are in the Methods section).
Fig. 8. Effect of 24 hours incubation with 100 U/ml IL-1, 5 ng/ml IL-6,
1000 U/ml TNF, 1 mg/ml LPS, or 5 mM butyrate on GalT6 activity in
human proximal tubular cells. (N 5 3 each data point). Control GalT6
activity was 0.38 6 0.07 densitometry units. Details are in the Methods
section.
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(5 mM) caused proximal tubular cells to look toxic and also
magnified CHX cytotoxicity. This suggests that high bu-
tyrate concentrations are directly injurious and may aug-
ment Stx-1 toxicity non-specifically.
The significance of Stx-1-induced proximal tubular cell
death is speculative, but several interesting possibilities are
evident. Proximal tubular cell dysfunction could be respon-
sible, at least in part, for the early and rapid onset of renal
failure seen in some patients with D1HUS. Such a hypoth-
esis is supported by the clinical observation of severe renal
failure in the absence of histologically apparent endothelial
cell or glomerular damage [2, 23]. Renal tubule damage
may also initiate or contribute to a cascade of events
leading to endothelial cell damage. For example, proximal
tubular cell injury might incite an early inflammatory
reaction that could affect neighboring endothelial, and
even glomerular, cells. This inflammatory reaction could
conceivably involve recruitment of inflammatory cells or
even release of inflammatory cytokines and other factors
that could alter adjacent cell function. Regardless of the
mechanism by which proximal tubular cell injury contrib-
utes to renal dysfunction in D1HUS, it is evident that this
cell type is exquisitely sensitive to Stx-1 and that inflamma-
tory factors likely to be elevated in the kidney of patients
with D1HUS augment proximal tubule responsiveness to
Stx-1. Clearly, the role of Stx-1 in damaging proximal
tubular cells, and the pathophysiologic significance of this
toxicity, is an area in need of further study.
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APPENDIX
Abbreviations used in this article are: CATTNF, chloramphenicol acetyl-
transferase reporter/tumor necrosis factor; CHX, cycloheximide;
D1HUS, post-diarrheal hemolytic uremic syndrome; DMEM, Dulbecco’s
modified Eagle media; GalT6, UDP-galactose lactosylceramide galacosyl-
transferase; GB3, galactose-a1,4, galactose-B-1,4, glucose-ceramide;
HBSS, Hank’s balanced salt solution; HUVEC, human umbilical vein
endothelial cells; IL, interleukin; LacCer, lactosylceramide; LPS, lipopoly-
saccharide; p(NH)ppA, 59-adenylimidodiphosphate; SDS, sodium dodecyl
sulfate; Stx, Shiga toxin; TBST, Tris buffered saline Tween 20; TCA,
tricarboxylic acid; TNF, tumor necrosis factor.
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